Literature DB >> 9182832

Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells.

J L Grem1, L K Yee, D J Venzon, C H Takimoto, C J Allegra.   

Abstract

PURPOSE: The activity of dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme in fluorouracil catabolism, has been reported to vary according to time of day. We wished to determine whether peak and trough DPD activities occurred at uniform times in six subjects, whether individual patterns fit a discernible profile, and whether such patterns were consistent and reproducible over time.
METHODS: Mononuclear cells were isolated from peripheral blood at 3-h intervals over a 24-h period on three different dates over a 6-month period. DPD activity was determined by incubating cellular lysates with [3H]FUra and measuring [3H]dihydrofluorouracil formation over time.
RESULTS: When the data were averaged by study date for each subject, the median value for the average DPD activity (11.0 pmol/min per 10(6) cells) was significantly different from both the median peak (21.1 pmol/min per 10(6) cells, P = 0.004) and median trough activities (4.0 pmol/min per 10(6) cells, P = 0.002). Within the six subjects, the average DPD activity for the three study dates differed by a median of 2.4-fold (range 1.2- to 4.8-fold). The time at which peak and trough DPD activities occurred varied between subjects: 8 of the 17 peaks (47%) occurred between 10:00 p.m. and 6:00 a.m., 6 (35%) occurred between 8:00 a.m. and 3:00 p.m., and 3 (18%) occurred between 5:00 p.m. and 8:15 p.m. Thus, the time of day when the peak occurred was essentially randomly distributed over the 24-h period of observation (P = 0.68). Ten (59%) of the trough DPD activities occurred between 7:00 a.m. and 3:00 p.m. The median interval between the peak and trough was 6.5 h. The data were also expressed as percent of the mean for each individual's 24-h sampling period, and reordered as time from peak rather than as the actual time of day. When the combined data for all cycles was considered, the trough occurred 6-9 h after the peak, and the DPD levels subsequent to the peak did not display merely random variation (P = 0.0055).
CONCLUSIONS: DPD activity levels and the times at which peak and trough DPD activities occurred varied both between and within subjects. If fluctuations in DPD activity influence the tolerability of fixed-rate infusions of FUra, these data suggest that a single variable-rate infusion regimen may not be suitable for all patients nor for a given individual treated over several months.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9182832     DOI: 10.1007/s002800050635

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  Analysis of pyrimidine catabolism in Drosophila melanogaster using epistatic interactions with mutations of pyrimidine biosynthesis and beta-alanine metabolism.

Authors:  John M Rawls
Journal:  Genetics       Date:  2005-12-15       Impact factor: 4.562

Review 2.  Pharmacogenetics: a tool for individualizing antineoplastic therapy.

Authors:  F Innocenti; L Iyer; M J Ratain
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 3.  Chronopharmacokinetics of ciclosporin and tacrolimus.

Authors:  Massimo Baraldo; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  Therapeutic drug monitoring of antimetabolic cytotoxic drugs.

Authors:  L Lennard
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

Review 5.  How may anticancer chemotherapy with fluorouracil be individualised?

Authors:  Su-arpa Ploylearmsaeng; Uwe Fuhr; Alexander Jetter
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 6.  Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.

Authors:  M T Paff; D P Baccanari; S T Davis; S Cao; R L Tansik; Y M Rustum; T Spector
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

Review 7.  5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development.

Authors:  J L Grem
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

8.  Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels.

Authors:  Hao Jiang; Jing Lu; Jiang Ji
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

9.  Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients.

Authors:  A B Van Kuilenburg; H van Lenthe; M J Blom; E P Mul; A H Van Gennip
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

Review 10.  Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase.

Authors:  Filippo Merloni; Nicoletta Ranallo; Laura Scortichini; Riccardo Giampieri; Rossana Berardi
Journal:  Cancer Drug Resist       Date:  2019-09-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.